The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...

Novo Nordisk’s Lars Fruergaard Jørgensen will step down as CEO of the weight-loss drug maker following a steep decline in share price over the last year.The Danish drugmaker said it was a “mutual ...

Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to ...

U.S.-listed shares of Novo Nordisk declined in the opening minutes of trading Friday on the surprise news that CEO Lars ...

As Novo Nordisk's share price drops, CEO Lars Fruergaard Jorgensen steps down. The company aims to maintain its lead in the ...

Novo Nordisk's CEO, Lars Fruergaard Jorgensen, will step down amidst market challenges and a significant stock price drop, ...

"Considering the recent market challenges, the share price decline, and the wish from the Novo Nordisk Foundation ... seem to be weighing heavily on the stock — down less than 3% in trading ...

Earnings grew barely 14% last quarter -- and over the past year, the stock has lost roughly half its value. The board cited these "recent market challenges Novo Nordisk has been facing ...

Lars Fruergaard Jørgensen will step down after eight years helming the Danish drugmaker, shares of which have shed half their ...

Ozempic maker Novo Nordisk NOVO.B-2.41%decrease; red down pointing triangle pushed out its chief executive after losing ground in the anti-obesity drug market, which has caused a steep stock-price ...

Novo Nordisk (NVO) stock falls as the company CEO Lars Fruergaard Jørgensen steps down after 8 years of leadership marked by surging profits & sales. Read more here.

"Considering the recent market challenges, the share price decline ... Read more about Novo Nordisk's stock moves and today's market action. After years of being known for its insulin and diabetes ...